13F Filings History of Knoll Capital Management, LLC
- Latest 13F filing
- Q1 2026 - 15 May 2026
- Latest reported 13F value
- $180,158,559
- Largest 13F holdings
-
BHVN PHYS RGLD MGTX AEM KGC ALDX SA FNV SSRM ELTX ENTX
+8 more
NUVB CGAU PAAS PSLV OCUL TFPM GROY AGI - Form 13F summary
-
- Knoll Capital Management, LLC Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
- Form 13F is generally due within 45 days after each calendar quarter ends.
- Knoll Capital Management, LLC reported 37 equity holdings with a total reported market value of $180,158,559 for Q1 2026. Top reported holdings included BHVN, PHYS, RGLD, MGTX, and AEM.
- Manager signature
- Fred Knoll - President
- Manager location
- Miami, FL
13F snapshot
Latest parsed holdings, value, and filing-period context.
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Knoll Capital Management, LLC with Pro and return when a new 13F portfolio filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
Holdings Value
Form 13F evidence
Quarterly portfolio filings
SEC-reported 13F quarters for this filer, ordered by the latest accepted filing.
Latest quarter
Q1 2026
Latest value
$180,158,559
Quarter delta
-$37,855,339
Accepted
15 May 2026, 16:00
Rows shown
1-25 of 51
| Quarter | Holdings | SEC-reported value | Bought | Sold | Net | Top Holdings | Form Type | Accepted by SEC |
|---|---|---|---|---|---|---|---|---|
| Q1 2026 | 37 | $180,158,559 | +$29,671,857 | -$39,540,986 | -$9,869,129 | BHVN, PHYS, RGLD, MGTX, AEM | 13F-HR | 15 May 2026, 16:00 |
| Q4 2025 | 33 | $218,013,898 | +$36,434,392 | -$12,236,610 | +$24,197,782 | ALDX, BHVN, NUVB, AVDL, GLD | 13F-HR | 17 Feb 2026, 16:04 |
| Q3 2025 | 38 | $186,187,654 | +$6,154,133 | -$10,170,602 | -$4,016,469 | ALDX, BHVN, GLD, ENTX, MGTX | 13F-HR | 14 Nov 2025, 16:21 |
| Q2 2025 | 38 | $138,451,856 | +$1,761,524 | -$4,107,979 | -$2,346,455 | ALDX, Biohaven Pharmactl Hldg Co L, ENTX, GLD, MGTX | 13F-HR | 14 Aug 2025, 16:00 |
| Q1 2025 | 36 | $153,726,702 | +$14,214,323 | -$12,798,297 | +$1,416,026 | ALDX, Biohaven Pharmactl Hldg Co L, ENTX, GLD, MGTX | 13F-HR | 15 May 2025, 16:01 |
| Q4 2024 | 35 | $155,344,595 | +$6,300,100 | -$1,160,528 | +$5,139,572 | BHVN, ALDX, ENTX, VRNA, ALT | 13F-HR | 14 Feb 2025, 20:12 |
| Q3 2024 | 36 | $206,982,383 | +$13,111,062 | -$76,841,183 | -$63,730,121 | APLT, BHVN, ALDX, AVDL, GLD | 13F-HR | 14 Nov 2024, 16:22 |
| Q2 2024 | 35 | $148,407,303 | +$11,524,328 | $0 | +$11,524,328 | APLT, BHVN, ALDX, AVDL, ALT | 13F-HR | 14 Aug 2024, 16:03 |
| Q1 2024 | 34 | $160,736,263 | +$19,176,390 | -$9,570,296 | +$9,606,094 | APLT, BHVN, ALDX, AVDL, GLD | 13F-HR | 15 May 2024, 16:05 |
| Q4 2023 | 32 | $120,759,584 | +$20,940,036 | -$7,513,200 | +$13,426,836 | BHVN, ALDX, APLT, AVDL, SIL | 13F-HR | 14 Feb 2024, 16:07 |
| Q3 2023 | 37 | $95,604,841 | +$24,991,113 | -$1,240,483 | +$23,750,630 | ALDX, APLT, BHVN, AVDL, HOOK | 13F-HR | 14 Nov 2023, 16:17 |
| Q2 2023 | 26 | $80,706,157 | +$20,989,080 | $0 | +$20,989,080 | ALDX, BHVN, AVDL, HOOK, APLT | 13F-HR | 15 Aug 2023, 07:50 |
| Q1 2023 | 24 | $57,025,930 | +$9,265,051 | -$1,914,806 | +$7,350,245 | ALDX, BHVN, VRNA, GDX, ENTX | 13F-HR | 15 May 2023, 16:25 |
| Q4 2022 | 21 | $43,699,802 | +$12,193,384 | -$16,497,027 | -$4,303,643 | ALDX, BHVN, ALT, GDX, SIL | 13F-HR | 14 Feb 2023, 16:06 |
| Q3 2022 | 33 | $169,877,000 | +$2,630,670 | -$11,573,020 | -$8,942,350 | BHVN, ALDX, ENTX, ALT, Anavex Life Sciences Corp | 13F-HR | 14 Nov 2022, 16:03 |
| Q2 2022 | 41 | $171,172,000 | +$6,037,834 | -$3,029,000 | +$3,008,834 | BHVN, ALDX, EIGR, ENTX, ORGS | 13F-HR | 15 Aug 2022, 17:22 |
| Q1 2022 | 41 | $158,723,000 | +$5,244,562 | -$5,683,266 | -$438,704 | BHVN, ENTX, EIGR, ORGS, ALDX | 13F-HR | 16 May 2022, 16:13 |
| Q4 2021 | 38 | $180,648,000 | +$9,017,992 | -$2,854,930 | +$6,163,062 | BHVN, APLT, ENTX, ORGS, Anavex Life Sciemves Corp | 13F-HR | 14 Feb 2022, 16:04 |
| Q3 2021 | 40 | $200,171,000 | +$912,000 | -$7,939,100 | -$7,027,100 | BHVN, APLT, ENTX, ORGS, CRBP | 13F-HR | 15 Nov 2021, 16:05 |
| Q2 2021 | 42 | $189,909,000 | +$9,468,891 | -$971,333 | +$8,497,558 | BHVN, APLT, ENTX, CRBP, ORGS | 13F-HR | 16 Aug 2021, 16:05 |
| Q1 2021 | 39 | $153,044,000 | +$16,214,290 | -$4,736,427 | +$11,477,863 | BHVN, APLT, CRBP, ORGS, ENTX | 13F-HR | 14 Jun 2021, 13:34 |
| Q4 2020 | 31 | $146,130,000 | +$4,617,473 | $0 | +$4,617,473 | BHVN, APLT, EIGR, CRBP, ORGS | 13F-HR | 16 Feb 2021, 16:08 |
| Q3 2020 | 30 | $121,534,000 | +$6,999,995 | -$1,567,611 | +$5,432,384 | BHVN, APLT, CRBP, ORGS, EIGR | 13F-HR | 16 Nov 2020, 16:08 |
| Q2 2020 | 19 | $173,219,000 | +$8,773,752 | -$2,246,000 | +$6,527,752 | BHVN, CRBP, APLT, ABEO, ORGS | 13F-HR | 14 Aug 2020, 16:11 |
| Q1 2020 | 18 | $106,461,000 | +$7,017,768 | -$6,464,975 | +$552,793 | BHVN, CRBP, APLT, ABEO, BX | 13F-HR | 15 May 2020, 16:01 |